Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rilzabrutinib - Principia Biopharma

Next Previous
Drug Profile

Rilzabrutinib - Principia Biopharma

Alternative Names: PRN 1008; SAR-444671

Latest Information Update: 22 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Principia Biopharma
  • Developer Principia Biopharma; Sanofi
  • Class 2 ring heterocyclic compounds; Amines; Anti-inflammatories; Antianaemics; Antiasthmatics; Fluorobenzenes; Nitriles; Phenyl ethers; Piperazines; Piperidines; Pyrazoles; Pyrimidines; Skin disorder therapies; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pemphigus; Pemphigus vulgaris; Idiopathic thrombocytopenic purpura
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Idiopathic thrombocytopenic purpura
  • Phase II Asthma; Atopic dermatitis; Autoimmune disorders; Autoimmune haemolytic anaemia; Chronic urticaria
  • Discontinued Pemphigus; Pemphigus vulgaris

Most Recent Events

  • 25 Mar 2024 Sanofi initiates a phase I bioavailability trial for Autoimmune disorders (in volunteers) in the US (NCT06342700)
  • 25 Mar 2024 Sanofi plans a phase I bioavailability trial in Autoimmune disorder (In volunteers) in March 2024 (PO, Tablet) (NCT06342700)
  • 15 Mar 2024 Discontinued - Phase-II for Pemphigus vulgaris in France, Israel, Croatia, Greece, Australia (PO), before March 2024 (Sanofi Pipeline, March 2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top